Uploaded August 2026 | Updated September 2026, 1 week ago

---

Alex Zhavoronkov, CEO of Insilico Medicine, on why we’re opening our core AI benchmarking tools to the entire industry.
It’s not about competing on model parameters – it’s about:
✅ Teaching cutting‑edge AI how to do drug discovery
✅ Validating with real‑world experimental data
✅ Making intelligence flow between algorithms and wet labs

“Our moat is the bridge that connects AI to real medicines.”

Our roadmap is clear:
🔹 Open benchmarks to help more models get smarter
🔹 Feed real drug R&D data back into AI
🔹 Turn breakthroughs into out‑licensable assets

At the end of the day, we just want AI to genuinely accelerate drug development – and get better treatments to patients sooner.
That’s not a slogan. It’s what we experiment on and iterate every single day.

🔬 We invite all AI teams to join us at dddbench.insilico.com – let’s build that bridge together.